Teleflex (NYSE:TFX – Get Rating) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share guidance of $13.70-$14.30 for the period. The company issued revenue guidance of $2.87 billion-$2.92 billion.Teleflex also updated its FY22 guidance to $13.70-14.30 EPS.
NYSE TFX opened at $288.69 on Friday. The firm has a market cap of $13.54 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 1.91 and a beta of 1.13. Teleflex has a one year low of $256.77 and a one year high of $428.36. The stock’s 50 day simple moving average is $320.39 and its 200 day simple moving average is $324.03. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.28 and a quick ratio of 1.53.
Teleflex (NYSE:TFX – Get Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical technology company reported $2.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.72 by $0.16. Teleflex had a return on equity of 17.24% and a net margin of 17.31%. The firm had revenue of $641.70 million for the quarter, compared to the consensus estimate of $631.89 million. During the same quarter in the prior year, the business earned $2.87 EPS. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. As a group, equities analysts expect that Teleflex will post 13.98 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 15th. Stockholders of record on Monday, May 16th will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date is Friday, May 13th. Teleflex’s dividend payout ratio (DPR) is currently 13.22%.
A number of research analysts have recently weighed in on TFX shares. Raymond James cut their price target on Teleflex from $391.00 to $370.00 and set an outperform rating on the stock in a research note on Wednesday, February 23rd. Truist Financial cut their price target on Teleflex from $370.00 to $340.00 in a research note on Friday, April 29th. Piper Sandler raised their price objective on Teleflex from $320.00 to $335.00 in a research note on Thursday, February 24th. Needham & Company LLC dropped their price objective on Teleflex from $425.00 to $400.00 and set a buy rating on the stock in a research note on Monday, January 31st. Finally, StockNews.com raised Teleflex from a hold rating to a buy rating in a research note on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Buy and a consensus price target of $388.46.
A number of hedge funds have recently added to or reduced their stakes in TFX. Eaton Vance Management increased its holdings in Teleflex by 141.3% during the 1st quarter. Eaton Vance Management now owns 284,639 shares of the medical technology company’s stock worth $100,999,000 after purchasing an additional 166,682 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Teleflex by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 5,147,062 shares of the medical technology company’s stock valued at $1,826,333,000 after acquiring an additional 83,858 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Teleflex by 49.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 203,728 shares of the medical technology company’s stock valued at $72,289,000 after acquiring an additional 67,538 shares in the last quarter. Bridgewater Associates LP grew its holdings in shares of Teleflex by 84.1% in the 1st quarter. Bridgewater Associates LP now owns 94,841 shares of the medical technology company’s stock valued at $33,652,000 after acquiring an additional 43,328 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Teleflex by 16.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 257,525 shares of the medical technology company’s stock valued at $91,377,000 after acquiring an additional 36,796 shares in the last quarter. Hedge funds and other institutional investors own 92.21% of the company’s stock.
Teleflex Company Profile (Get Rating)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Featured Articles
Receive News & Ratings for Teleflex Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teleflex and related companies with MarketBeat.com’s FREE daily email newsletter.
from NYSE Updates – My Blog https://ift.tt/DQ6aOMz
via IFTTT
No comments:
Post a Comment